

IN THE SPECIFICATION

Please replace the paragraph beginning at page 4, line 11, with the following rewritten paragraph:

Pitavastatins used in the present invention include the compound pitavastatin ((3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)3-quinolyl]-3,5-dihydroxy-6-heptenoic acid: Japanese Patent No. 2569746, US Patent No. 5856336 and European Patent No. 304063), lactone ring-forming substances thereof and salts of pitavastatin, and the salts of pitavastatin include pitavastatin sodium and pitavastatin calcium. Further, they include hydrates thereof and solvates thereof with solvents which are allowable as medicines. Pitavastatin calcium is the most preferred as of the pitavastatins.